Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021071

« Back to Dashboard

NDA 021071 describes AVANDIA, which is a drug marketed by Sb Pharmco and is included in one NDA. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the AVANDIA profile page.

The generic ingredient in AVANDIA is rosiglitazone maleate. There are twelve drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the rosiglitazone maleate profile page.

Summary for 021071

Tradename:	AVANDIA
Applicant:	Sb Pharmco
Ingredient:	rosiglitazone maleate
Patents:	1
Therapeutic Class:	Blood Glucose Regulators
Formulation / Manufacturing:	see details

Pharmacology for NDA: 021071

Ingredient-type	PPAR gamma Thiazolidinediones
Mechanism of Action	Peroxisome Proliferator-activated Receptor Activity

Suppliers and Packaging for NDA: 021071

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071	NDA	GlaxoSmithKline LLC	0173-0861	N	0173-0861-18
AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071	NDA	GlaxoSmithKline LLC	0173-0863	N	0173-0863-13

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	EQ 2MG BASE
Approval Date:	May 25, 1999	TE:	AB	RLD:	Yes
Patent:	➤ Try a Free Trial	Patent Expiration:	Oct 19, 2020	Product Flag?		Substance Flag?		Delist Request?	Y

Profile for product number 003

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	EQ 4MG BASE
Approval Date:	May 25, 1999	TE:	AB	RLD:	Yes
Patent:	➤ Try a Free Trial	Patent Expiration:	Oct 19, 2020	Product Flag?		Substance Flag?		Delist Request?	Y

Profile for product number 004

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	EQ 8MG BASE
Approval Date:	May 25, 1999	TE:	AB	RLD:	Yes
Patent:	➤ Try a Free Trial	Patent Expiration:	Oct 19, 2020	Product Flag?		Substance Flag?		Delist Request?	Y

Expired US Patents for NDA 021071

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sb Pharmco	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-003	May 25, 1999	➤ Try a Free Trial	➤ Try a Free Trial
Sb Pharmco	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-003	May 25, 1999	➤ Try a Free Trial	➤ Try a Free Trial
Sb Pharmco	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-004	May 25, 1999	➤ Try a Free Trial	➤ Try a Free Trial
Sb Pharmco	AVANDIA	rosiglitazone maleate	TABLET;ORAL	021071-002	May 25, 1999	➤ Try a Free Trial	➤ Try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.